Related Experiment Video

Updated: May 23, 2026

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
07:08

A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status

Published on: October 20, 2016

Identification of biomarkers in Lewy-body disorders

L Warr1, Z Walker

  • 1North Essex Partnership Foundation NHS Trust, Essex, UK.

The Quarterly Journal of Nuclear Medicine and Molecular Imaging : Official Publication of the Italian Association of Nuclear Medicine (AIMN) [And] the International Association of Radiopharmacology (IAR), [And] Section of the Society Of
|March 31, 2012
PubMed

Insights

Accurate diagnosis of Lewy body disorders like dementia with Lewy bodies (DLB) is crucial. Biomarkers, especially dopamine transporter imaging, show promise for distinguishing DLB from Alzheimer's disease and Parkinson's disease dementia.

Area of Science:

  • Neurology
  • Neuroscience
  • Biomarker Discovery

Background:

  • Dementia with Lewy bodies (DLB) is a common dementia subtype, often presenting with overlapping symptoms with Alzheimer's disease (AD) and Parkinson's disease dementia (PDD).
  • Current diagnostic criteria for DLB versus PDD rely on symptom onset timing, highlighting the need for more definitive diagnostic tools.
  • Accurate and early diagnosis is essential for effective patient management and treatment strategies in Lewy body disorders.

Purpose of the Study:

  • To review and assess the current landscape of biomarkers for diagnosing Dementia with Lewy bodies (DLB).
  • To evaluate the reliability and specificity of various imaging and non-imaging techniques in differentiating DLB from other neurodegenerative conditions.
  • To emphasize the potential of combined biomarker approaches for improving diagnostic accuracy.

Main Methods:

  • Review of existing literature on biomarkers for DLB, AD, and PDD.
  • Analysis of imaging techniques including [123I]FP-CIT-SPECT, cardiac 123I-MIBG scintigraphy, FDG-PET, and CT/MRI.
  • Consideration of non-imaging biomarkers such as cerebrospinal fluid (CSF) protein levels and electroencephalography (EEG).

Main Results:

  • Reduced dopamine transporter levels ([123I]FP-CIT-SPECT) are identified as a highly reliable biomarker for DLB.
  • Other promising imaging biomarkers include reduced cardiac 123I-MIBG uptake and occipital hypometabolism on FDG-PET.
  • While CSF biomarkers and other methods show potential, findings are less consistent; combination approaches demonstrate high sensitivity and specificity.

Conclusions:

  • Biomarker development is critical for improving the accuracy of DLB diagnosis.
  • Dopamine transporter imaging and a combination of multiple biomarkers show the most promise for clinical application.
  • Longitudinal studies and pathological confirmation are key for validating new biomarkers in Lewy body disorders.

More Related Videos

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains09:27

Sequential Extraction of Soluble and Insoluble Alpha-Synuclein from Parkinsonian Brains

Published on: January 5, 2016

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

Related Concept Videos

Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
Neural Regulation01:37

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
Parkinson Disease l: Introduction01:24

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...